



BC Centre for Disease Control  
Provincial Health Services Authority

Communicable Diseases and Immunization Service  
655 West 12th Avenue  
Vancouver, BC V5Z 4R4

Tel 604.707.2548  
Fax 604.707.2515  
[www.bccdc.ca](http://www.bccdc.ca)

**Date: May 25, 2020**

**Administrative Circular: 2020:11**

**ATTN:** Medical Health Officers and Branch Offices  
Public Health Nursing Administrators and Assistant Administrators  
Holders of Communicable Disease Control Manuals

**Re: Update to Communicable Disease Control Manual, Chapter 2: Immunization,  
Part 1 – Immunization Schedules and Part 4 – Biological Products**

### **Part 1 – Immunization Schedules**

#### **2.1 Schedule A: Basic Immunization for Children Starting Series at 2 Months of Age**

- Footnote A has been revised to indicate that the 3 dose primary series of DTaP-containing vaccine should be completed with the product from the same manufacturer whenever possible.
- Footnote B has been revised to indicate that either Menveo® or Nimenrix® should be given to high risk infants in place of Men-C-C at 2, 4 and 12 months of age.

#### **2.2 Schedule B: Children 1 to 6 Years of Age (Inclusive) When Starting or Resuming Immunization**

- Footnote A has been revised to indicate that the 3 dose primary series of DTaP-containing vaccine should be completed with the product from the same manufacturer whenever possible.

#### **3.1 Minimum Intervals Between Vaccine Doses Table**

- The table has been revised to indicate a minimum age for Nimenrix® of 6 weeks and has been included with Menveo® for minimum spacing recommendations between doses.

**Please remove page numbers: 5, 6 and 13 dated April and June 2018  
Please add new page numbers: 5, 6 and 13 dated May 2020**

Page 1 of 3

## **Part 4 – Biological Products**

### **Meningococcal Vaccines**

#### **Meningococcal Quadrivalent Conjugate Vaccines (Groups A,C,Y,W-135): Menveo®, Menactra®, Nimenrix®**

- “Doses and Schedule” has been revised to indicate that Nimenrix® can be used for children 2-23 months of age.
- Footnote F has been revised to indicate that booster doses may be recommended for those with ongoing risk of exposure. This includes individuals for whom the vaccine is recommended by NACI but not provided free in BC.
- Footnote G has been added to indicate that a 2<sup>nd</sup> dose of meningococcal quadrivalent conjugate vaccine may be considered for those 12-23 months of age if they will be traveling to a hyperendemic area. This dose is not provided free in BC.

**Please remove page numbers: 1-3 dated May 2017**  
**Please add new page numbers: 1-3 dated May 2020**

If you have any questions or concerns, please contact Stephanie Meier, Senior Practice Leader, BCCDC (telephone: 604-707-2577 / email: [stephanie.meier@bccdc.ca](mailto:stephanie.meier@bccdc.ca)).

Sincerely,



Monika Naus MD MHSc FRCPC FACPM  
Medical Director  
Communicable Diseases & Immunization Service  
BC Centre for Disease Control

pc:

Provincial Health Officer  
Dr. Bonnie Henry

Dr. Reka Gustafson  
Vice President, Public Health &  
Wellness, PHSA & Deputy Provincial  
Health Officer

BC Ministry of Health, Population &  
Public Health Division:

Brian Sagar  
Acting Senior Director Communicable  
Disease, Population and Public Health  
Division

Sarah Amyot  
Acting Executive Director,  
Public Health Services